Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1951 to 1965 of 9085 results

  1. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Awaiting development Reference number: GID-TA11855 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]

    Awaiting development Reference number: GID-TA11892 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. ProKnow cloud-based system for radiotherapy data storage, communication and management

    Awaiting development Reference number: GID-HTG10178 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  6. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  14 July 2026

    Technology appraisal guidance
    Awaiting development

  7. Vamikibart for treating uveitic macular oedema ID6671

    In development Reference number: GID-TA11885 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ianalumab for treating active Sjogren's disease ID6634

    In development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]

    Awaiting development Reference number: GID-TA11849 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]

    In development Reference number: GID-HST10069 Expected publication date:  11 April 2027

    Highly specialised technologies guidance
    In development

  11. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Deucravacitinib for treating active Sjogren's disease [ID6715]

    Awaiting development Reference number: GID-TA11939 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date:  10 June 2027

    Technology appraisal guidance
    Awaiting development

  14. Transnasal Panendoscopy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. External stimulation of the auricular branch of the vagus nerve

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation